Mohammad Hirmand
Director/Board Member chez AADI BIOSCIENCE, INC.
Profil
Le Dr Mohammad Hirmand, MD, est médecin en chef et vice-président exécutif de Turning Point Therapeutics, Inc. Auparavant, le Dr Hirmand a occupé les postes de vice-président du développement clinique chez Medivation LLC (Californie), de directeur associé de la recherche clinique chez Amgen, Inc., de directeur principal du développement clinique chez ARCA biopharma, Inc. et de directeur du développement du marché et de l'évaluation des produits chez Innoviva, Inc, directeur principal du développement clinique chez Nuvelo, Inc, directeur médical chez Peloton Therapeutics, Inc, directeur du développement oncologique chez SuperGen, Inc, directeur chez Theravance Biopharma US, Inc, et directeur des données cliniques chez Tularik, Inc. Il a obtenu son diplôme de premier cycle à l'Université Cornell et un doctorat à la Harvard Medical School.
Postes actifs de Mohammad Hirmand
| Sociétés | Poste | Début |
|---|---|---|
| AADI BIOSCIENCE, INC. | Director/Board Member | 27/03/2023 |
Avenzo Therapeutics, Inc.
 Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Founder | - |
Anciens postes connus de Mohammad Hirmand
| Sociétés | Poste | Fin |
|---|---|---|
| TURG POIN | Chief Tech/Sci/R&D Officer | 01/08/2022 |
| PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2019 |
| MEDIVATION INC | Chief Operating Officer | 01/10/2015 |
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| ARCA BIOPHARMA, INC. | Corporate Officer/Principal | - |
Formation de Mohammad Hirmand
| Cornell University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| INNOVIVA, INC. | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| AADI BIOSCIENCE, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
| Nuvelo, Inc. | Health Technology |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Commercial Services |
